Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable: an evidence review group perspective of a NICE single technology appraisal

Ren, S. orcid.org/0000-0003-3568-7124, Squires, H. orcid.org/0000-0002-2776-4014, Hock, E. orcid.org/0000-0002-8617-8875 et al. (3 more authors) (2019) Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 37 (9). pp. 1073-1080. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Springer Nature Switzerland AG 2018. This is an author produced version of a paper subsequently published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published (online): 13 December 2018
  • Published: 1 September 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Funding Information:
FunderGrant number
NATIONAL INSTITUTE FOR HEALTH RESEARCH14/25/02
Depositing User: Symplectic Sheffield
Date Deposited: 17 Jan 2019 14:08
Last Modified: 16 Nov 2021 09:41
Status: Published
Publisher: Springer Nature
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-018-0750-2

Share / Export

Statistics